This week’s vaccines update highlights key clinical findings, regulatory developments, and emerging platforms shaping the future of prevention across oncology, respiratory pathogens, and aging-related disease.
In Today’s Newsletter
Dive deeper
🦠 Datar Cancer Genetics’ Phase 1 Cancer Vaccine Trial Update [IN • 1 Dec 2025]
Context: Bombay High Court directed the formation of an expert panel to review the company’s plea for approval of Phase 1 trials for its cancer immunotherapy drug, Per-C-Vax. The court has requested a report within three months.
Key point: The company is pushing for approval of its indigenous cancer vaccine, arguing the vaccine’s potential to put India on the global map.
Implication: A significant step forward in India’s cancer vaccine development, contingent on expert review.
🧬 GC Biopharma’s MAV/06 Vaccine Receives WHO Endorsement [KR • 2 Dec 2025]
Context: GC Biopharma’s proprietary varicella vaccine strain MAV/06 was included in the WHO Position Paper on varicella vaccination.
Key point: MAV/06’s inclusion solidifies the status of BARYCELA Inj., GC Biopharma’s varicella vaccine, as a globally recognized alternative.
Implication: WHO endorsement strengthens GC Biopharma’s position in international vaccine markets and procurement platforms like PAHO.
💉 Shingles Vaccine May Slow Dementia Progression [US • 2 Dec 2025]
https://edition.cnn.com/2025/12/02/health/shingles-vaccine-dementia-progression-study-wellness
Context: New research suggests that the shingles vaccine may not only prevent shingles but also slow dementia’s progression.
Key point: The study indicates the shingles vaccine could have therapeutic properties, potentially reducing dementia-related death rates.
Implication: This opens the door for the shingles vaccine to serve as a preventive measure against dementia, adding new benefits to its existing protective role.
🧪 ILiAD Biotechnologies Reports Successful BPZE1 Phase 2b Results [US • 3 Dec 2025]
Context: ILiAD Biotechnologies’ BPZE1 vaccine has shown significant protection against whooping cough in its Phase 2b clinical trial, demonstrating a 97% reduction in bacterial burden.
Key point: BPZE1’s ability to protect against B. pertussis colonization is the first of its kind in a human challenge model.
Implication: With favorable safety data, BPZE1 could play a pivotal role in preventing pertussis outbreaks, especially given the growing challenge of vaccine effectiveness.
👶 New Nasal Spray Vaccine for Whooping Cough Shows Promise [UK • 3 Dec 2025]
https://www.bbc.com/news/articles/cp8zv522e8mo
Context: A new nasal spray vaccine for whooping cough, BPZE1, developed in the UK, could offer longer-lasting protection and stop the bacteria from being carried and spread.
Key point: The vaccine triggers strong immune responses in both the nasal mucosa and bloodstream, marking a significant advancement in pertussis prevention.
Implication: If further trials confirm its efficacy, BPZE1 could become a major tool in the fight against whooping cough, reducing transmission across populations.
Why it matters
- Cancer Vaccine Development: India’s push for indigenous cancer vaccine trials could set a precedent for similar initiatives in emerging markets.
- WHO Recognition: GC Biopharma’s WHO endorsement highlights the growing importance of validated vaccines in global public health.
- Shingles Vaccine and Dementia: If confirmed, the link between shingles vaccination and dementia progression could lead to major shifts in vaccine recommendations for older adults.
- Pertussis Control: BPZE1’s innovative approach could address gaps in current pertussis vaccination efforts, reducing transmission and improving global health outcomes.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
📚 View the full Vaccines archive on our research hub page
FAQ
What is the current status of Datar Cancer Genetics’ vaccine trial?
The Bombay High Court has directed an expert panel to review the company’s plea for Phase 1 human trials, with a report expected in three months. [1]
How does GC Biopharma’s MAV/06 vaccine stand out?
MAV/06’s inclusion in the WHO Position Paper underscores its equivalence to other leading varicella vaccines, enhancing its global recognition and supply stability. [2]
What potential does the shingles vaccine have for dementia?
Emerging research suggests the shingles vaccine might slow dementia progression and reduce death rates from dementia, offering broader protective benefits for older adults. [3]
How effective is the BPZE1 pertussis vaccine?
BPZE1 has demonstrated over 97% protection against whooping cough in Phase 2b trials, with strong immune responses in both nasal and systemic tests. [4]
What is the significance of the new nasal spray vaccine for whooping cough?
The BPZE1 nasal spray offers potential for longer-lasting protection and could stop the spread of pertussis, particularly among adults and children, providing broad community-level protection. [5]
Entities / Keywords
Datar Cancer Genetics; GC Biopharma; MAV/06; WHO Position Paper; Shingles Vaccine; Dementia; ILiAD Biotechnologies; BPZE1; Pertussis; Whooping Cough; Nasal Spray Vaccine.
References
- https://indianexpress.com/article/cities/mumbai/bombay-hc-seeks-panel-report-plea-seeking-human-trials-cancer-vaccine-10395274/
- https://www.biospace.com/press-releases/gc-biopharmas-varicella-vaccine-strain-mav-06-listed-in-who-position-paper
- https://edition.cnn.com/2025/12/02/health/shingles-vaccine-dementia-progression-study-wellness
- https://www.businesswire.com/news/home/20251201920333/en/ILiAD-Biotechnologies-Announces-Lancet-Microbe-Publication-of-BPZE1-Phase-2b-Clinical-Results-in-Human-Challenge-Model
- https://www.bbc.com/news/articles/cp8zv522e8mo